

Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk

Web: www.wwl.nhs.uk

Ref: FOI/2024/10454

Date Received: 23rd January 2025

Response Due: 20th February 2025

Date: 12th February 2025

Dear Sir/Madam

With reference to your request for information received on 23rd January 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

July 2024 = 6.

August 2024 = 12.

September 2024 = 10.

October 2024 = 23.

November 2024 = 23.

December 2024 = 16.

*The above patients are regarding inpatients only. The figures are based off admissions where the diagnosis in any position was DLBCL (C83.3).

a. Of these patients, how many commenced treatment at your trust within the last 6 months?

The Trust is unable to provide this data as it is not recorded centrally, if recorded it would be held within individual case notes. As case notes are for the care and treatment of patients, we do not request staff to interrogate them in order to collate the information required to respond to Freedom of Information requests.

2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 5.

- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) = 0.**
 - **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) = 0.**
 - **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) = 8.**
 - **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**
 - **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) = 0.**
 - **R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) = 0.**
 - **(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) = 0.**
 - **R-GemOX (rituximab, gemcitabine and oxaliplatin) = 0.**
 - **Axicabtagene ciloleucel = 0.**
 - **Tisagenlecleucel = 0.**
 - **Epcoritamab = 0.**
 - **Loncastuximab tesirine = 0.**
 - **Glofitamab = 0.**
 - **Any other SACT = <5 (R-CEOP).**
 - **Stem cell transplant or bone marrow transplant (autologous or allogeneic) = 0.**
- 3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):**
- **Axicabtagene ciloleucel (Yescarta) = 0.**
 - **Tisagenlecleucel = 0.**
 - **Pola-BR (polatuzumab vedotin with rituximab and bendamustine) = 0.**
 - **R-GemOX (rituximab, gemcitabine and oxaliplatin) = 0.**
 - **Stem cell transplant or bone marrow transplant (autologous or allogeneic) = 0.**
 - **Any other treatments = 0.**
- 4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?**
0.
- 5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:**
- **CAR-T Therapy (E.g. Axicabtagene ciloleucel) = 0.**
 - **Stem cell transplant or bone marrow transplant (autologous or allogeneic) = 0.**
 - **Any other treatment = 0.**

The Trust has a standard procedure of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Hazel Hendriksen', followed by a long horizontal flourish.

Hazel Hendriksen
Divisional Director of Operations for Specialist Services

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111